Brief: Toleranzia Postpones Start Of Its Clinical Trial With TOL2

Toleranzia AB

11/11/2021 15:16

Nov 11 (Reuters) - Toleranzia AB  TOLE.ST :
    * START OF TOLERANZIA'S PLANNED CLINICAL TRIAL WITH TOL2
POSTPONED
DUE TO GLOBAL SHORTAGE OF CERTAIN MATERIALS FOR PRODUCTION OF
THE DRUG SUBSTANCE
    * CLINICAL TRIAL WILL BE POSTPONED UNTIL SECOND HALF OF 2023
DUE
TO CONTINUED GLOBAL SHORTAGE OF MATERIALS
    * STUDY WAS PREVIOUSLY EXPECTED TO BE INITIATED BEFORE END
OF
2022/23.
    * GLOBAL SHORTAGE OF MATERIALS NECESSARY FOR PURIFICATION OF
TOL2,
WHICH IS ALSO USED IN PRIORITIZED MANUFACTURING OF COVID-19
VACCINES

Source text for Eikon:  ID:nMFN3518Ky 
Further company coverage:  TOLE.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))